logo

Genprex, Inc. (GNPX)



Trade GNPX now with
  Date
  Headline
6/23/2021 8:36:14 AM Genprex:Phase 1/2 Acclaim-1 Trial Begun For REQORSA Immunogene Therapy With Tagrisso To Treat NSCLC Following FDA Review
3/30/2021 8:36:32 AM Genprex Reports Preclinical Data For TUSC2 Immunogene Therapy In NSCLC To Be Featured In Two Presentations
2/9/2021 8:34:23 AM Genprex Announces $25 Mln Direct Offering
1/13/2021 9:06:47 AM Genprex Says Achieves Major Manufacturing Milestone For REQORSAImmunogene Therapy For Upcoming Trials To Treat NSCLC
12/24/2020 1:07:42 PM Genprex Announces Closing Of $12 Mln Registered Direct Offering
12/22/2020 9:40:14 AM Genprex Completes Manufacturing Scale-Up For Clinical-Grade Production Of REQORSA Immunogene Therapy
11/10/2020 8:20:04 AM Genprex Announces Addition Of George Gittes To Scientific Advisory Board
10/29/2020 8:21:42 AM Genprex Receives Conditional FDA Acceptance Of Proprietary Name REQORSA For Lead Drug Candidate For NSCLC Treatment
10/26/2020 8:18:32 AM Genprex Promote Eric Chapdelaine To VP Of Manufacturing
9/21/2020 8:21:39 AM Genprex Appoints Thomas Gallagher As SVP Of Intellectual Property And Licensing
9/2/2020 8:19:48 AM Genprex Appoints William Gannon, Jr. As VP Of Regulatory Affairs
6/25/2020 8:20:54 AM Genprex: USAN Council Approves Non-proprietary Name Quaratusugene Ozeplasmid For GPX-001
5/28/2020 8:20:01 AM Genprex Receives $2.5 Mln In Cash From Recent Warrant Exercises
4/21/2020 8:19:08 AM Genprex Appoints Shannon Inman As VP Of Global Clinical Operations
3/24/2020 8:24:46 AM Genprex Appoints Brent Longnecker, Jose Moreno Toscano And William Wilson To Board
3/23/2020 8:21:22 AM Genprex Appoints Catherine Vaczy As EVP And Chief Strategy Officer And Michael Redman As EVP And Chief Operating Officer
2/19/2020 9:25:24 AM Genprex Prices $17.50 Mln Common Stock Offering At-The-Market And Without Warrants